Ligand reported a 51% year-over-year increase in royalty revenue to $70.3 million and raised full-year Adjusted Diluted EPS guidance to $9.50 to $9.75. The results reflect performance from key assets like Filspari and the XOMA acquisition.
Ligand reported a 51% year-over-year increase in royalty revenue to $70.3 million and raised full-year Adjusted Diluted EPS guidance to $9.50 to $9.75. The results reflect performance from key assets like Filspari and the XOMA acquisition.